Technology ID
TAB-4882
Advancements in HIV-1 Therapeutics: Development of Trispecific Antibodies via Second-Generation CD4-Binding Site Integration
E-Numbers
E-066-2020-0
Lead Inventor
Lusso, Paolo
Lead IC
NIAID
Co-Inventors
Liu, Qingbo
Mascola, John
Pegu, Amarendra ("Amar")
Asokan, Mangaiarkarasi
Kwon, Young Do
Kwong, Peter
Koup, Richard
Yang, Zhi-yong
ICs
NIAID
Applications
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Discovery
Research Products
Plasmids/Vectors
Human Cell Lines
Antibodies
The discovery of a secondary CD4-binding site has led to a breakthrough in the efficacy of HIV-1 neutralizing antibodies. Sanofi's development of trispecific antibodies incorporating this site promises enhanced neutralization and T-cell stimulation. This advancement diverges from prior methods by engrafting the FR3 loop of another antibody, granting new functional properties. The potential extension of this technique to bi- or tri-specific antibodies could transform HIV-1 therapeutic strategies. Documentation and exploration of this innovation are crucial for advancing treatment modalities and improving patient outcomes.
Commercial Applications
The discovery of a second CD4-binding site on HIV-1 antibodies enables more effective virus neutralization and immune response. This innovation paves the way for personalized, potent antibody treatments, potentially overcoming viral resistance. Its application could extend to other viral infections, marking a significant advancement in immunotherapy. This breakthrough has the potential to transform global health strategies.
Competitive Advantages
The discovery of a second CD4-binding site has led to antibodies with heightened neutralization capabilities and prolonged activity in HIV-1 treatment. Sanofi's trispecific antibodies, leveraging this advancement, offer improved patient outcomes through enhanced potency and T-cell response. This innovation sets a new standard for antibody therapeutics, potentially reducing viral resistance. The ability to document and refine this technology underpins its competitive advantage in the fast-evolving pharmaceutical landscape.
Licensing Contact: